Elon Musk’s Neuralink is set to transform vision restoration with its Blindsight implant, a brain-computer interface (BCI) designed to restore sight for the blind, including those with severe optic nerve damage or congenital blindness. Announced for human trials by late 2025, Blindsight has received FDA “breakthrough device” designation, accelerating its development. Here’s how it works and what to expect. Blindsight implants a microelectrode array into the brain’s visual cortex, bypassing damaged eyes or optic nerves. The array, with over 1,000 electrodes, stimulates neurons based on signals from an external camera, creating visual perceptions. Unlike retinal implants, it targets the brain directly, enabling vision for those blind from birth, provided their visual cortex is intact. Initial resolution will be low, akin...